FDA cleared and CLIA-waived a new group A streptococcus molecular test for decentralized use on Diasorin’s Liaison Nes point-of-care PCR instrument. The test delivers results in about 15 minutes with under one minute of hands-on time and uses room-temperature-stable reagents, targeting the high-volume clinical setting of acute pharyngitis. Diasorin said the assay is the second on the Liaison Nes platform, after the earlier respiratory panel clearance and CLIA waiver for influenza A, influenza B, RSV, and COVID-19. The company also reiterated that it is working to expand the Nes menu and has longer-term revenue targets discussed at a recent investor day. For laboratories and care settings operating outside traditional lab workflows, the clearance widens the menu of FDA-authorized rapid molecular testing options and strengthens the platform’s positioning against other near-patient PCR systems.